PMID- 36428809
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20221213
IS  - 2072-6694 (Print)
IS  - 2072-6694 (Electronic)
IS  - 2072-6694 (Linking)
VI  - 14
IP  - 22
DP  - 2022 Nov 21
TI  - Epidemiological Study of p16 Incidence in Head and Neck Squamous Cell Carcinoma 
      2005-2015 in a Representative Northern European Population.
LID - 10.3390/cancers14225717 [doi]
LID - 5717
AB  - The incidence of human papillomavirus (HPV)-associated head and neck squamous 
      cell carcinomas (HNSCC) has increased globally. Our research goal was to study 
      HNSCC incidence in a representative Northern European population and evaluate the 
      utility of the HPV surrogate marker p16 in clinical decision-making. All new 
      HNSCC patients diagnosed and treated in Southwest Finland from 2005-2015 (n = 
      1033) were identified and analyzed. During the follow-up period, the incidence of 
      oropharyngeal (OPSCC) and oral cavity squamous cell carcinoma (OSCC) increased, 
      while the incidence of laryngeal squamous cell carcinoma (LSCC) decreased. This 
      clinical cohort was used to generate a population-validated tissue microarray 
      (PV-TMA) archive for p16 analyses. The incidence of p16 positivity in HNSCC and 
      OPSCC increased in southwest Finland between 2005 and 2015. p16 positivity was 
      mainly found in the oropharynx and was a significant factor for improved 
      survival. p16-positive OPSCC patients had a better prognosis, regardless of 
      treatment modality. All HNSCC patients benefited from a combination of 
      chemotherapy and radiotherapy, regardless of p16 expression. Our study reaffirms 
      that p16 expression offers a prognostic biomarker in OPSCC and could potentially 
      be used in cancer treatment stratification. Focusing on p16 testing for only 
      OPSCC might be the most cost-effective approach in clinical practice.
FAU - Mylly, Mari
AU  - Mylly M
AD  - Department for Otorhinolaryngology, Head and Neck Surgery, University of Turku 
      and Turku University Hospital, Kiinamyllynkatu 4-8, 20521 Turku, Finland.
FAU - Nissi, Linda
AU  - Nissi L
AD  - Department of Oncology, University of Turku and Turku University Hospital, 
      Kiinamyllynkatu 4-8, 20521 Turku, Finland.
FAU - Huusko, Teemu
AU  - Huusko T
AD  - Department for Otorhinolaryngology, Head and Neck Surgery, University of Turku 
      and Turku University Hospital, Kiinamyllynkatu 4-8, 20521 Turku, Finland.
FAU - Routila, Johannes
AU  - Routila J
AUID- ORCID: 0000-0001-5385-7065
AD  - Department for Otorhinolaryngology, Head and Neck Surgery, University of Turku 
      and Turku University Hospital, Kiinamyllynkatu 4-8, 20521 Turku, Finland.
FAU - Vaittinen, Samuli
AU  - Vaittinen S
AD  - Department of Pathology, Turku University Hospital and Turku University, 
      Kiinamyllynkatu 10, 20521 Turku, Finland.
FAU - Irjala, Heikki
AU  - Irjala H
AD  - Department for Otorhinolaryngology, Head and Neck Surgery, University of Turku 
      and Turku University Hospital, Kiinamyllynkatu 4-8, 20521 Turku, Finland.
FAU - Leivo, Ilmo
AU  - Leivo I
AD  - Biomedical Institute, University of Turku, Kiinamyllynkatu 10, 20520 Turku, 
      Finland.
FAU - Ventela, Sami
AU  - Ventela S
AUID- ORCID: 0000-0001-6672-6662
AD  - Department for Otorhinolaryngology, Head and Neck Surgery, University of Turku 
      and Turku University Hospital, Kiinamyllynkatu 4-8, 20521 Turku, Finland.
AD  - Turku Bioscience Centre, University of Turku and Abo Akademi University, 
      Tykistokatu 6, 20520 Turku, Finland.
LA  - eng
GR  - Finnish Medical Foundation/
GR  - the Finnish ORL-HNS Research Foundation/
GR  - State Research Funding/
GR  - Kirsti and Tor Johansson Heart and Cancer Foundation/
GR  - Finnish Cultural Foundation/
PT  - Journal Article
DEP - 20221121
PL  - Switzerland
TA  - Cancers (Basel)
JT  - Cancers
JID - 101526829
PMC - PMC9688375
OTO - NOTNLM
OT  - HNSCC
OT  - HPV
OT  - OPSCC
OT  - epidemiology
OT  - incidence
OT  - p16
OT  - survival
COIS- The authors declare no conflict of interest. The funders had no role in the 
      design of the study; in the collection, analyses, or interpretation of data; in 
      the writing of the manuscript, or in the decision to publish the results.
EDAT- 2022/11/27 06:00
MHDA- 2022/11/27 06:01
PMCR- 2022/11/21
CRDT- 2022/11/26 01:05
PHST- 2022/10/18 00:00 [received]
PHST- 2022/11/11 00:00 [revised]
PHST- 2022/11/18 00:00 [accepted]
PHST- 2022/11/26 01:05 [entrez]
PHST- 2022/11/27 06:00 [pubmed]
PHST- 2022/11/27 06:01 [medline]
PHST- 2022/11/21 00:00 [pmc-release]
AID - cancers14225717 [pii]
AID - cancers-14-05717 [pii]
AID - 10.3390/cancers14225717 [doi]
PST - epublish
SO  - Cancers (Basel). 2022 Nov 21;14(22):5717. doi: 10.3390/cancers14225717.